Sunlenca Kit
Product Images NDC 61958-3002

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sunlenca (NDC 61958-3002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Sunlenca 01)

The text seems to describe a Vial access device with a syringe injection needle. However, the meaning of "x2" next to each other is not clear in this context.*

FDA Label Image

Figure 2 (Sunlenca 02)

The text contains instructions on how to prepare a vial of yellow solution with no particles in it. It specifies the amount of solution to be drawn using a syringe and the need to expel air bubbles. There are also instructions on how to inject the solution into the patient's abdomen subcutaneously using an injection needle. The text also emphasizes the need for a clean vial stopper, a non-expired product, and wiping the contents. There is a reminder to inject at least two inches away from the navel and to choose a different site for the second injection.*

FDA Label Image

Chemical Structure (Sunlenca 03)

FDA Label Image

Principal Display Panel (300 mg Tablet Blister Pack Pouch Carton)

NDC 61958-3001-1 is the code for Sunlenca tablets that contain 300mg per tablet of lenacapavir, with one pouch containing four tablets. The tablets should be stored within a temperature range of 20°C to 25°C (68°F to 77°F) and kept in the original container. The recommended dosage should be obtained from the prescribing information, and caution should be taken to keep the product out of reach of children. The tablets are manufactured by Gilead Sciences, Inc. and are made in Canada.*

FDA Label Image

Principal Display Panel (5 Tablet Blister Pack Pouch Carton)

Sunlenca tablets are a medication containing 300 mg of Lenacapavir per tablet, which is present as 306.8 mg Lenacapavir Sodium. The tablets come in a pouch of 5 tablets and should be stored at 20-25 °C. They are manufactured by Gilead Sciences, Inc. in Canada and contain NDC 61958-3001-2. The recommended dosage and directions for use are available in the prescribing information. It is advisable to consult a healthcare provider before taking these tablets, and they should be kept out of children's reach.*

FDA Label Image

Principal Display Panel (Kit Carton)

This is a medication called "Lenacapavir" with the NDC code of 61958-3002-1. It is for subcutaneous injection and comes with two 1.5mL single-dose vials, 2 vial access devices, 2 syringes, and 2 injection needles (22 gauge, 1/2 inch). The package also includes Prescribing Information, Instructions for Use, and Patient Information. To receive the recommended dose of 927 mg, both 463.5 mg/1.5mL vials need to be administered. It is for healthcare professionals' administration only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.